We propose to employ highly novel technologies of biospectroscopy and human intestinal organoid culture to develop a humanised in vitro model of Crohn's disease fibrosis. Additionally, we aim to develop biomarkers of fibrosis which can be utilised in the clinical setting for rapid patient stratification for therapy. This will lead to improved cost effective and personalised medicine, resulting in better patient outcomes and reduced healthcare costs.
|Effective start/end date||1/01/19 → 31/12/21|
- The Gutsy Group Inc: AUD145,548.00